The purpose of the study is to determine whether the combination of these two medicines is safe and works better than chemotherapy alone in slowing the disease. In the early part of the trial, different dose levels are tried to find the highest amount that can be given without causing unacceptable side effects, known as the “maximum tolerated dose.” Later, participants are randomly assigned to receive either the combination or the chemotherapy alone, and the time they live without the cancer getting worse, called “progression‑free survival,” is measured.

Participants would visit the clinic for regular intravenous infusions of the study drugs, followed by routine check‑ups that may include physical exams and imaging tests such as scans to see how the tumor is responding. The study lasts for several months, with visits scheduled to monitor health, record any side effects, and assess whether the cancer is stable, shrinking, or growing.

The study will be conducted in two phases. In the first phase, the goal is to determine the safest and most effective dose of the combination of selinexor and gemcitabine. In the second phase, the study will evaluate how well this combination works in preventing the cancer from getting worse over a period of six months. Participants will receive the treatment and be monitored regularly to assess their response to the medication and any side effects they may experience.

Throughout the study, participants will undergo various assessments to monitor their health and the progress of their cancer. These assessments will include regular check-ups and tests to ensure the treatment is working as intended and to manage any potential side effects. The study aims to provide valuable information on the effectiveness and safety of using selinexor and gemcitabine together for treating advanced soft-tissue sarcomas.

The purpose of the study is to find the best dose of these medications when used together and to see how effective they are in treating the cancer. The study is divided into two phases. In the first phase, researchers will determine the safest and most effective dose of the combination treatment. In the second phase, they will evaluate how well the treatment works by looking at how long patients live without the cancer getting worse over a period of six months.

Participants in the study will receive the combination of selinexor and gemcitabine. Some participants may receive a placebo instead of selinexor. The study will monitor the participants’ health and any side effects they experience. The overall goal is to improve the treatment options for people with advanced soft-tissue sarcoma by finding a combination of medications that can help control the disease more effectively.

The purpose of the study is to evaluate the safety and tolerability of CEB-01 when used alongside standard cancer treatments. The study will involve children from birth to under 18 years of age who have these specific types of tumors. Participants will receive the new treatment in addition to their usual care, and the effects will be compared to those who receive only the standard treatment. The study will monitor for any side effects and how well the treatment works in preventing the cancer from coming back or spreading.

Throughout the study, researchers will collect information on the participants’ health and how their bodies process the treatment. This includes measuring the levels of the drug in the blood and observing any changes in the tumors. The study aims to provide valuable information on the potential benefits and risks of using CEB-01 in treating these childhood cancers.

The purpose of this research is to test how well patients tolerate Liposomal Annamycin when given weekly and to determine how effective it is in treating metastatic soft-tissue sarcomas. The study is divided into two parts: the first part focuses on finding the right dose that can be safely given to patients, while the second part examines how well the treatment works.

The study involves patients who have already received previous treatment for their cancer, including prior therapy with anthracycline medications. During the study, participants will receive Liposomal Annamycin treatment, and their response to the medication will be monitored through regular medical examinations and imaging tests. The treatment will continue as long as patients show benefit from it and do not experience unacceptable side effects.

The purpose of this study is to find the best dose of the combination of Sutent and Opdivo and to see how well this combination works in stopping the cancer from getting worse. The study is divided into different stages and groups, with some groups receiving different combinations of treatments. For example, one group will receive Sutent and Opdivo together, while another group will receive Opdivo with other chemotherapy drugs like epirubicin and ifosfamide. The study will also look at how safe these treatments are and how they affect the patients’ overall health.

Participants in the study will receive their assigned treatments and will be monitored over time to see how their cancer responds. The study aims to determine how long patients can live without their cancer getting worse and to assess the overall survival rate. The trial will also collect information on any side effects experienced by participants to ensure the treatments are as safe as possible. The study is expected to continue until 2025, with the goal of improving treatment options for people with advanced soft tissue and bone sarcomas.

The purpose of this study is to assess how well Cirtuvivint works in preventing the cancer from getting worse over a period of three months. Participants in the trial will receive Cirtuvivint and will be monitored to see how their cancer responds to the treatment. The study will also look at the safety of the medication and how well patients tolerate it. This will involve regular check-ups and tests to monitor any side effects and overall health. The trial aims to provide valuable information on the effectiveness and safety of Cirtuvivint for patients with these specific types of sarcomas.

Throughout the study, participants will be asked to avoid certain activities, such as extensive sun exposure and the use of tanning salons, to ensure the best possible results. The trial will last for a period of time, with regular follow-ups to track the progress of the treatment. By participating in this study, researchers hope to gain a better understanding of how Cirtuvivint can be used to help manage advanced soft-tissue sarcomas and improve the quality of life for patients affected by these cancers.

The purpose of this study is to explore different ways of using PM14, both on its own and in combination with radiotherapy, which is a treatment that uses high doses of radiation to kill cancer cells and shrink tumors. The study is divided into different groups, or cohorts, each testing a specific treatment plan. Some groups will receive PM14 alone, while others will receive PM14 along with radiotherapy. The study aims to find the best dose of PM14 that can be safely used and to see how well it works in stopping the cancer from growing or spreading.

Participants in the study will receive PM14 in different schedules, such as a 24-hour infusion or shorter infusions over consecutive days. The study will also look at how the treatment affects the participants’ quality of life and any side effects they may experience. The trial will provide valuable information about the potential benefits and risks of PM14 for treating these types of cancers, helping to determine if it could be a useful option for patients in the future.

Participants in the study will receive the treatment over a period of time, with regular monitoring to assess how their body responds to the medication. The study will look at both the local effects at the site of the tumor and the overall effects on the body. The goal is to determine the best dose of BT-001 and to see how well it works when used with pembrolizumab. Some participants may receive a placebo as part of the study to help compare the effects of the actual treatment.

Throughout the study, participants will undergo various assessments to monitor their health and the progression of their cancer. This includes regular check-ups and tests to ensure the treatment is safe and to measure its impact on the cancer. The study aims to provide valuable information on the potential benefits of combining BT-001 with pembrolizumab for treating these challenging types of cancer.

The treatment combines two medications: cobimetinib (taken as tablets by mouth) and atezolizumab (given through an intravenous infusion into a vein). Cobimetinib works by blocking specific proteins called MEK1 and MEK2 that can cause cancer cells to grow, while atezolizumab helps the immune system fight cancer cells by targeting a protein called PDL1.

The study is conducted in two parts. The first part checks if the combination of medications is safe for children aged 6 months to 12 years. The second part examines how well the treatment works in different groups of patients based on their specific type of sarcoma. Patients will receive the treatment and undergo regular medical evaluations to monitor their response to the medications and any side effects that may occur.

Participants in the study will receive the combination of Trabectedin and radiotherapy. The study will monitor how well the treatment works and any side effects that may occur. The goal is to determine the most effective and safe dose of Trabectedin when used with radiotherapy. The study will also look at how the treatment affects the cancer’s response and the chances of the cancer returning over a period of five years.

The study is divided into different groups, each receiving specific doses of Trabectedin to find the most suitable one. The researchers will collect information on how the cancer responds to the treatment and any side effects experienced by the participants. This information will help in understanding the best way to use Trabectedin with radiotherapy for treating soft tissue sarcoma.

The purpose of this study is to evaluate the safety and effectiveness of these treatments in helping the immune system fight cancer. Participants in the study will receive the treatments over a period of six months. The DC-VACCINE_IRSTIRCCS is given through an injection into the skin, while Proleukin is administered as an injection under the skin. Throughout the study, participants will be monitored for any side effects and changes in their immune response to the cancer.

The study aims to understand how well these treatments work in preventing the return of cancer and improving overall survival. Researchers will also look at how the treatments affect the immune system’s ability to target cancer cells. The study will help determine if these treatments can be a safe and effective option for patients with these rare cancers.

The trial will include patients with various types of advanced cancers, such as non-small cell lung cancer, renal cell carcinoma, urothelial bladder cancer, head and neck squamous cell cancer, breast cancer, gastric or gastroesophageal adenocarcinoma, epithelial ovarian cancer, cervical cancer, endometrial adenocarcinoma, prostate cancer, and soft tissue sarcoma. The study will be conducted in two phases. The first phase will focus on finding the right dose of JK06 by gradually increasing the amount given to patients. The second phase will involve giving the selected dose to more patients to further evaluate its effects.

Throughout the study, patients will receive the treatment every three weeks and will be monitored closely for any side effects or changes in their condition. The goal is to gather information that will help in developing JK06 as a potential treatment option for people with these types of advanced cancers. The study is expected to continue until 2028, with recruitment starting in 2024.

The purpose of this study is to evaluate how well the combination of Nivolumab and Relatlimab works in controlling the cancer over a period of six months. Participants in the study will receive these medications through an intravenous infusion, which means the drugs are given directly into a vein. The study will monitor the participants’ response to the treatment, looking for signs that the cancer is shrinking, staying the same, or growing. The trial will also assess the safety of the treatment combination and any side effects that may occur.

Throughout the study, participants will undergo regular medical check-ups and imaging tests, such as MRI or CT scans, to track the progress of their cancer. These tests help doctors determine how the cancer is responding to the treatment. The study aims to provide valuable information on the effectiveness of combining Nivolumab and Relatlimab for treating advanced or metastatic soft-tissue sarcoma, potentially offering new hope for patients with this challenging condition.

The purpose of the study is to evaluate how many patients show a reduction in tumor size when treated with these medications. Participants will receive the treatment over a period of time, and their response to the treatment will be monitored using imaging techniques. The study will also look at the safety of the treatment and how it affects the quality of life of the participants.

Throughout the study, researchers will collect information to understand how the treatment works and identify any markers that might predict how well a patient responds to the therapy. This information could help improve treatment strategies for patients with soft tissue sarcoma in the future.

The purpose of the study is to evaluate how well this combination treatment works in preventing the cancer from getting worse over a period of six months. Participants in the study will be randomly assigned to one of two groups: one group will receive both Atezolizumab and SBRT, while the other group will receive only SBRT. The study will monitor the participants’ health and the progression of their cancer over time to determine the effectiveness of the treatment.

Throughout the study, participants will undergo regular check-ups and assessments to track their response to the treatment. The study will also look at various factors such as the overall survival of participants, their quality of life, and any side effects they may experience. The information gathered from this trial will help researchers understand the potential benefits and risks of combining Atezolizumab with SBRT for treating soft tissue sarcomas.

The study will involve several steps. Initially, patients will receive three cycles of chemotherapy with doxorubicin, followed by surgery to remove the tumor. Some patients will receive additional cycles of chemotherapy before surgery to see if this improves their chances of staying cancer-free. After surgery, patients may also receive radiotherapy, which uses high-energy rays to target and kill any remaining cancer cells. The main goal is to see if this approach helps patients live longer without the cancer coming back or spreading.

Throughout the study, doctors will monitor patients closely to see how well the treatment is working and to check for any side effects. The study will last for several years to gather enough information to determine if the intensified chemotherapy approach is beneficial. The results will help doctors understand if this treatment plan can be used to improve the care of patients with high-risk soft-tissue sarcoma in the future.

The purpose of this study is to evaluate how well Berzosertib works in combination with Gemcitabine in treating patients with advanced or metastatic leiomyosarcoma. The study will compare the effectiveness of the combination treatment to Gemcitabine alone. Participants in the study will receive either the combination of Berzosertib and Gemcitabine or Gemcitabine by itself. The study will monitor the participants over a period to see how the cancer responds to the treatments, specifically looking at whether the cancer shrinks, remains stable, or progresses.

Throughout the study, participants will receive their treatments through an intravenous infusion, which means the medication is delivered directly into the bloodstream through a vein. The study aims to determine the safety and effectiveness of the treatments, as well as to gather information on any side effects experienced by the participants. The results of this study could provide valuable insights into new treatment options for patients with leiomyosarcoma.

The purpose of the study is to see if Tislelizumab can help improve the time patients remain free from cancer after treatment, known as disease-free survival. Patients will receive either Tislelizumab or a placebo and will be monitored over a period of time to assess their health and any changes in their condition. The study will involve regular check-ups and assessments to track the progress of the patients and the effectiveness of the treatment.

Participants in the study will be those who have completed their initial cancer treatments, such as surgery or chemotherapy, and have been identified as having MRD. The study will include patients with certain types of cancer, such as non-small cell lung cancer, colorectal cancer, pancreatic cancer, and soft-tissue sarcoma. The trial aims to provide valuable information on whether Tislelizumab can offer additional benefits in preventing cancer recurrence in these patients.

During the study, patients will receive either cyclophosphamide tablets or doxorubicin infusions. Some patients may also receive additional medications including filgrastim (a drug that helps the body produce white blood cells) and dexrazoxane hydrochloride (a medication that helps protect the heart from potential side effects of doxorubicin). The treatment will continue until the cancer progresses or side effects become too severe.

Throughout the treatment period, doctors will monitor patients’ overall health, cancer progression, and quality of life. They will perform regular medical examinations and tests to check how well the treatment is working and to watch for any side effects. Special attention will be given to elderly patients’ specific health needs and their ability to perform daily activities.

The purpose of the study is to find out if the combination of L19TNF and dacarbazine can help patients live longer without their cancer getting worse, compared to using dacarbazine alone. Patients in the study will receive the treatment through an intravenous infusion, which means the medication will be given directly into a vein. Some patients will receive the combination of both drugs, while others will receive only dacarbazine or a placebo. The study will last for a period of up to 48 weeks, during which time patients will be monitored regularly to check on their health and the progress of their cancer.

Throughout the study, doctors will look at how well the treatment works by measuring how long patients live without their cancer getting worse, which is known as progression-free survival. They will also look at overall survival, which is the length of time patients live after starting the treatment. This study aims to provide new insights into the treatment of advanced or metastatic soft-tissue sarcoma and potentially offer a new option for patients who have not had success with other treatments.

The purpose of the study is to find out if the combination of L19TNF and doxorubicin is more effective than using doxorubicin alone. Participants in the study will receive either the combination of the two drugs or just doxorubicin. Some participants may receive a placebo, which is a substance with no active drug, to help compare the effects of the treatment. The study will involve regular visits to the clinic for treatment and monitoring, which includes physical exams and laboratory tests to check the safety and effectiveness of the treatment.

The trial will continue for a period of time to gather enough information to determine the benefits and risks of the new treatment combination. The main goal is to see if the new treatment can help patients live longer without their cancer getting worse, which is referred to as progression-free survival. The safety of the treatment will also be closely monitored throughout the study.

The study is divided into two phases. The first phase aims to find the safest and most effective dose of LB-100 when given with doxorubicin. The second phase compares how well patients do when treated with either the combination of both drugs or doxorubicin by itself. Both medications are given through an intravenous infusion (directly into a vein).

The research specifically looks at several types of soft tissue sarcomas, including undifferentiated pleomorphic sarcoma and leiomyosarcoma. Doctors will monitor how long patients live without their disease getting worse, track any side effects, and assess the overall survival of participants. They will also evaluate how the treatments affect patients’ quality of life during the study.

The study combines two types of treatment: a medication called trabectedin (given through an intravenous infusion) and low-dose radiation therapy. Trabectedin is administered as a solution that is prepared from a powder and given through a special tube placed in a vein. The dose used in this study is 1.5 milligrams per square meter of body surface.

The main goal of this research is to determine how well tumors respond to this combination treatment, particularly in areas that receive radiation therapy. Throughout the study, researchers will monitor changes in tumor size, track how long the treatment remains effective, and assess its effects on pain levels and overall well-being. They will also carefully watch for any side effects that may occur during treatment.

The purpose of the study is to determine if this additional chemotherapy can help prevent the cancer from spreading to other parts of the body, which is known as metastasis. Participants in the study will receive up to four cycles of chemotherapy, with each cycle lasting a few weeks. The study will compare the outcomes of patients receiving this treatment with those who receive the standard management for Soft Tissue Sarcoma.

Throughout the study, the health and progress of the participants will be closely monitored to assess the safety and effectiveness of the treatment. The main focus will be on how long patients remain free from metastasis, as well as their overall survival and any side effects experienced during the treatment. The study is expected to continue for several years to gather comprehensive data on the long-term benefits and risks of the chemotherapy regimen being tested.

Participants in the study will receive either the GnRHa treatment or a placebo, which is a substance with no active medication. The GnRHa treatment being studied is called Pamorelin, which is given as an injection. There are two different doses of Pamorelin being used in the study: 3.75 mg and 11.25 mg. The study will follow participants for several years to monitor their ovarian reserve and other health factors. This includes measuring levels of a hormone called Anti-Müllerian Hormone (AMH), which helps indicate the number of eggs left in the ovaries, at various points after the end of chemotherapy.

Throughout the study, participants will have regular check-ups to assess their ovarian reserve and overall health. This will involve tests like ultrasounds and blood tests to measure hormone levels. The study aims to provide valuable information on how GnRHa might help preserve fertility in young women and teenagers undergoing cancer treatment. By understanding the effects of this treatment, researchers hope to improve future care for patients facing similar challenges.

The purpose of the study is to evaluate how effective the combination of these two treatments is in controlling the disease. Patients participating in the trial will receive these medications through an intravenous infusion, which means the drugs are administered directly into the bloodstream. The study will monitor patients over a period to see how their cancer responds to the treatment.

Throughout the trial, patients will undergo regular assessments to track the progress of their disease. These assessments will help determine if the cancer is shrinking, staying the same, or growing. The study aims to provide valuable information on whether this combination of treatments can help manage more effectively. Participants will be closely monitored by healthcare professionals to ensure their safety and well-being during the trial.